Meet the Start-ups


Daniel Jansen | CEO | Vedea Healthware

Founder/CEO Daniel Jansen is, first and foremost, a father of 3 children, one of them a daughter with amblyopia. Consequently, he has firsthand experience of the impact occlusion therapy has on a child and the parent-child relationship.
Combining his personal experiences with his background in software development, digital marketing and sales, Daniel brings a unique perspective to Vedea, aiming to raise awareness of the Vedea method among parents and children who are currently navigating a similar journey to his own from a few years ago.


With founder/CTO Joel Wijngaarde, Vedea has secured a highly reliable software architect with years of experience in crafting bespoke applications and platforms for both commercial and non-profit sectors. He will spearhead the development and support of the platform, as well as oversee AI development and data management.

With the addition of co-founders Teun Aalbers and Jan Jonk, renowned for their extensive and proven track record in game innovation within healthcare, Vedea is poised to integrate cutting-edge gaming experiences into its approach. Leveraging his background in scientific research, Teun Aalbers will bridge the gap between theory and practice. CCO Jan Jonk will lead the development of games and other experiences that infuse the Vedea method with vibrancy and engagement. 



Vedea Healthware

Amblyopia (more commonly known as 'lazy eye') is clinically defined as reduction of visual acuity in one or both eyes, caused by abnormal binocular interaction during the critical period of visual development, that cannot be attributed to any ocular or visual system abnormality or to refractive error.

With an incidence of 3% to 6%, amblyopia is the most common cause of low visual acuity in children and adults in developed countries and has great economic and social impact.

In Europe alone there are 1M children age 5-9 with amblyopia and globally 4 to 5 million children are diagnosed with the disorder each year..

Some studies predict the number of people affected by amblyopia worldwide will more than double by 2040. 

Vedea is developing a novel highly scalable low cost VR therapy, using over-the-counter mobile technology. 


Powered by:
Hyphen Projects   

    Connect     

Join Global Investor Forum

Privacy Policy
Terms & Conditions 
Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01
         
 
 

                                    

          Register here
 
© Copyright 2023 by Hyphen Projects